Kura Oncology, Inc. (KURA) SEC Filing 8-K Material Event for the period ending Tuesday, March 5, 2019

Kura Oncology, Inc.

CIK: 1422143 Ticker: KURA

View differences made from one to another to evaluate Kura Oncology, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kura Oncology, Inc..


Assess how Kura Oncology, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kura Oncology, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Kura Oncology, Inc. provided additional information to their SEC Filing as exhibits

Ticker: KURA
CIK: 1422143
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-064084
Submitted to the SEC: Tue Mar 05 2019 4:21:03 PM EST
Accepted by the SEC: Tue Mar 05 2019
Period: Tuesday, March 5, 2019
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: